Get the Stockscreener App
17.50
25.34%
3.538
After Hours:
17.50
0.002
+0.01%
Apollomics Inc stock is traded at $17.50, with a volume of 45,615.
It is up +25.34% in the last 24 hours and up +16.65% over the past month.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
See More
Previous Close:
$13.96
Open:
$13.88
24h Volume:
45,615
Relative Volume:
5.21
Market Cap:
$38.43M
Revenue:
$8.50M
Net Income/Loss:
$-10.94M
P/E Ratio:
-2.3115
EPS:
-7.57
Net Cash Flow:
$-28.76M
1W Performance:
+27.72%
1M Performance:
+16.65%
6M Performance:
+15.73%
1Y Performance:
+188.75%
1-Day Range:
$13.88
$18.93
1-Week Range:
$12.88
$18.93
52-Week Range:
$3.659
$42.12
Apollomics Inc Stock (APLM) Company Profile
Compare APLM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
17.50 | 38.43M | 8.50M | -10.94M | -28.76M | -7.57 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apollomics Inc Stock (APLM) Latest News
Apollomics Inc (APLMW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Apollomics Inc (APLMW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Apollomics Inc (APLMW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Apollomics Inc (APLM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Apollomics Inc (APLM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Apollomics Inc (APLM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Apollomics (APLM) CFO RSU vesting triggers 3,588-share tax withholding - Stock Titan
Apollomics Inc (APLM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Apollomics Inc (APLM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Apollomics Inc (APLM) Institutional Confidence - TradingKey
Apollomics Inc (APLM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Apollomics (APLM) CEO Hung-Wen Chen gains 5,000 shares as RSUs vest - Stock Titan
Apollomics (APLM) director acquires 500 shares through RSU vesting - Stock Titan
Apollomics (APLM) director vests 500 RSUs into Class A shares - Stock Titan
Apollomics (APLM) director receives 500 shares from RSU vesting - Stock Titan
[Form 4] Apollomics Inc. Insider Trading Activity - Stock Titan
Director at Apollomics (APLM) gains 500 shares from vested RSUs - Stock Titan
Apollomics Inc (APLMW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Apollomics Inc (APLMW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Apollomics Inc. (APLM) Faces Pressure Amid Recent Decline – Key Levels to WatchBearish Pattern Stocks - newsline.com
Behavioral Patterns of APLM and Institutional Flows - Stock Traders Daily
[EFFECT] Apollomics Inc. SEC Filing - Stock Titan
APLM SEC FilingsAPOLLOMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Apollomics Inc. (APLM) Edges Higher as Stock Tests Resistance Near $14.86Volume Profile - The Legal Advocate
(APLM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Apollomics Inc. Warrant (APLMW) Trades Flat at $0.01 Amid Minimal ActivityLow Volatility Picks - newsline.com
Apollomics Inc. Warrant (APLMW) Stalls at $0.01: Micro-Cap Warrant Holds Steady Amid Minimal Trading ActivitySmart Beta Flow - The Legal Advocate
Apollomics Inc. Warrant (APLMW) Holds Steady Near Minimal Levels – A Closer Look at the Biotech DerivativeCup and Handle - The Legal Advocate
Apollomics Warrants (APLMW) Hold at $0.01 After Modest Gain – Tight Trading Range PersistsCommunity Buy Alerts - Newser
APLMW Technical Analysis | Trend, Signals & Chart Patterns | APOLLOMICS INC-27 (NASDAQ:APLMW) - ChartMill
Apollomics Inc. (APLMW) Warrants Trade at $0.01 After Double-Digit DeclineSell Signal Alerts - Newser
Apollomics (APLM) director converts 500 RSUs into Class A shares - Stock Titan
How (APLM) Movements Inform Risk Allocation Models - Stock Traders Daily
Apollomics Inc. (APLM) files F-3/A to register 279,775 Class A shares - Stock Titan
Is Apollomics (APLM) Still a Buy After +10.29% Rally? 2026-05-15Investment Picks - newser.com
Apollomics (APLM) Climbs +0.54% — Resistance at $14.28 in Focus 2026-05-14Social Buy Zones - newser.com
TradingKey - TradingKey
What to expect when Apollomics (APLMW) reports earnings |Hold Rating - Newser
Trading Systems Reacting to (APLM) Volatility - Stock Traders Daily
The labor dynamics in Apollomics (APLM) results |Inventory Turnover - newser.com
APLMW | Apollomics Inc. Warrant Insider Trading - Quiver Quantitative
Is Apollomics (APLMW) dividend sustainable? (Smart Money Exits) 2026-04-29Expert Verified Trades - newser.com
Apollomics (Nasdaq: APLM) slashes 2025 loss amid cost cuts and new vebreltinib deal revenue - Stock Titan
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - marketscreener.com
How Apollomics Inc. (APLM) Affects Rotational Strategy Timing - Stock Traders Daily
APLM Apollomics highlights oncology pipeline progress and upcoming clinical trial milestones in its latest quarterly earnings report.Gamma Squeeze - Newser
APLM: Strategic restructuring and licensing revenue reduced losses, but liquidity and going concern risks persist - TradingView
Apollomics (NASDAQ: APLM) warns on going concern, defers vebreltinib NDA and writes down asset - Stock Titan
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Apollomics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Apollomics Inc Stock (APLM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):